药械

订阅

MedSci主页 / 所有栏目 / 药械

罗氏贝伐单抗新适应症获美国FDA快速审批

2014-07-18 佚名 不详

贝伐单抗罗氏
关注

大智慧阿思达克通讯社7月16日讯，罗氏公司周二宣布，美国食品药品监督管理局（FDA）已经授予Avastin（贝伐单抗）联合化疗治疗女性宫颈癌的优先审批通道。 罗氏的临床III期研究结果显示，贝伐单抗联合化疗能延长晚期宫颈癌女性患者寿命，目前每年有25万人因宫颈癌去世。 贝伐单抗最早于2004年2月在美国FDA获批，适应症包括肠癌、肺癌和肾癌等。根据罗氏财报，该药在2013年度销售额达62.

大智慧阿思达克通讯社7月16日讯，罗氏公司周二宣布，美国食品药品监督管理局（FDA）已经授予Avastin（贝伐单抗）联合化疗治疗女性宫颈癌的优先审批通道。

罗氏的临床III期研究结果显示，贝伐单抗联合化疗能延长晚期宫颈癌女性患者寿命，目前每年有25万人因宫颈癌去世。

贝伐单抗最早于2004年2月在美国FDA获批，适应症包括肠癌、肺癌和肾癌等。根据罗氏财报，该药在2013年度销售额达62.54亿瑞士法郎（合433.4亿人民币）。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1935107, encodeId=b57b193510e8d, content=<a href='/topic/show?id=25fe5204e49' target=_blank style='color:#2F92EE;'>#快速审批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52047, encryptionId=25fe5204e49, topicName=快速审批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Jul 31 06:12:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336688, encodeId=f031133668894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416193, encodeId=6ee7141619384, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58708, encryptionId=a24f58e0879, topicName=新适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476949, encodeId=54ff14e694935, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551363, encodeId=82c21551363f0, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2014-07-31 xugc

    #快速审批#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1935107, encodeId=b57b193510e8d, content=<a href='/topic/show?id=25fe5204e49' target=_blank style='color:#2F92EE;'>#快速审批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52047, encryptionId=25fe5204e49, topicName=快速审批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Jul 31 06:12:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336688, encodeId=f031133668894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416193, encodeId=6ee7141619384, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58708, encryptionId=a24f58e0879, topicName=新适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476949, encodeId=54ff14e694935, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551363, encodeId=82c21551363f0, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2014-07-20 644982816_68283321

    #适应症#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1935107, encodeId=b57b193510e8d, content=<a href='/topic/show?id=25fe5204e49' target=_blank style='color:#2F92EE;'>#快速审批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52047, encryptionId=25fe5204e49, topicName=快速审批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Jul 31 06:12:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336688, encodeId=f031133668894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416193, encodeId=6ee7141619384, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58708, encryptionId=a24f58e0879, topicName=新适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476949, encodeId=54ff14e694935, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551363, encodeId=82c21551363f0, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2014-07-20 docwu2019

    #新适应症#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1935107, encodeId=b57b193510e8d, content=<a href='/topic/show?id=25fe5204e49' target=_blank style='color:#2F92EE;'>#快速审批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52047, encryptionId=25fe5204e49, topicName=快速审批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Jul 31 06:12:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336688, encodeId=f031133668894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416193, encodeId=6ee7141619384, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58708, encryptionId=a24f58e0879, topicName=新适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476949, encodeId=54ff14e694935, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551363, encodeId=82c21551363f0, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2014-07-20 sunrural_42825359

    #贝伐#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1935107, encodeId=b57b193510e8d, content=<a href='/topic/show?id=25fe5204e49' target=_blank style='color:#2F92EE;'>#快速审批#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52047, encryptionId=25fe5204e49, topicName=快速审批)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Thu Jul 31 06:12:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336688, encodeId=f031133668894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416193, encodeId=6ee7141619384, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58708, encryptionId=a24f58e0879, topicName=新适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476949, encodeId=54ff14e694935, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551363, encodeId=82c21551363f0, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a46914191431, createdName=10518098zz, createdTime=Sun Jul 20 00:12:00 CST 2014, time=2014-07-20, status=1, ipAttribution=)]
    2014-07-20 10518098zz

    #美国FDA#

    0

相关资讯

Anticancer Res：S-1、伊立替康联合贝伐单抗治疗转移性结直肠癌患者的II期试验

背景：伊立替康可引起S期特异性细胞死亡，其活性代谢物SN-38是由羧酸酯酶催化的。长时间暴露于低浓度的伊立替康与饱和的羧酸酯酶，可增强治疗效果（Houghton PJ，1995，Rothenberg ML，1998）。曾报道过口服UFT/亚叶酸钙或S-1联合24小时输注伊立替康是非常有效的。因此对S-1、24小时输注伊立替康联合贝伐单抗治疗转移性结直肠癌（mCRC）的有效性和安全性进行了研究。

ASCO 2014：贝伐单抗加化疗用于直肠癌术前治疗的II期临床试验

对于局部晚期直肠癌（LARC），在高质量的全直肠系膜切除术（TME ）中允许省略术前放化疗(PCRT)，局部复发的情况不很常见。疾病转移的风险可部分通过磁共振成像（MRI）获得预测。然而术前放化疗并不能惠及所有的LARC患者，且与长期的患病率相关。 化疗（ Cty ）可减少局部复发的机会，但术后辅助化疗的依从性差，因此CRT后化疗的疗效已受到质疑。新辅助化疗手段正在原发性结肠癌和直肠癌（FOXTR

Cancer Chemother Pharmacol：贝伐单抗应用延长与NF2患者长期毒性相关

贝伐单抗疗法可使约半数、并发进展性前庭神经鞘瘤的2型神经纤维瘤(NF2)患者发生肿瘤萎缩和听力改善;高血压和蛋白尿是该疗法常见的两种副反应。然而，还尚未见有关贝伐单抗在该类人群中长期毒性方面的报道。 美国学者研究发现，贝伐单抗应用延长与可控性毒性之间具有关联性。然而，应用贝伐单抗疗法仍需对血压和蛋白尿进行仔细监测，未来的研究应探讨最佳的给药方案，以尽量减少长期毒性。论文发表于《癌症化疗与药理学》

ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）

来自东部肿瘤协作组织（ECOG）的E5103研究是首个关于毒性反应的研究。这项Ⅲ期随机试验比较了多柔比星、环磷酰胺和紫杉醇添加/不添加贝伐单抗时用于HER2阴性乳腺癌治疗的效果。 贝伐单抗可以延长转移性乳腺癌患者的无进展生存期（PFS），但不能改善其总生存（OS）。 E5103研究在HER2阴性乳腺癌的辅助治疗中添加贝伐单抗以评估贝伐单抗在乳腺癌辅助治疗中的作用。 按照1:2:2将患者随机分配

ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳

本研究为随机II-III期临床研究，研究的目的在于评估在广泛期小细胞肺癌患者中，在一线标准化疗的基础上联合贝伐单抗的治疗方案的有效性和安全性，来自于法国胸部肿瘤协作组的研究者们在ASCO 2014上发表了研究的摘要。 研究者所纳入的受试者为小细胞肺癌患者， 受试者先进行两个疗程的标准化疗作为诱导治疗，两次治疗的间隔时间为3周（顺铂-依托泊甙，或顺铂-环磷酰胺-表阿霉素-依托泊甙）。 如果受试者对诱

NEJM：贝伐单抗一线治疗不改善新诊胶质母细胞瘤生存

替莫唑胺联合放疗序贯替莫唑胺维持治疗是新诊胶质母细胞瘤的标准治疗。贝伐单抗是一种人源化单克隆抗体（抗血管内皮生长因子A），目前已被批准用于复发性胶质母细胞瘤。增加贝伐单抗是否会改善新诊胶质母细胞瘤患者的生存还不清楚。美国德克萨斯大学M.D. Anderson癌症中心的Mark R. Gilbert医生开展了一项双盲、安慰剂对照的Ⅲ期试验，论文发表于国际权威杂志NEJM 2014年2月在线版上。